Indeed, miR-519a associated with worse prognosis in luminal BrC patients, directly targeting the transcripts of cyclin dependent kinase inhibitor 1A (CDKN1A) and phosphatase and tensin homolog (PTEN), allowing for enhanced signaling of the phosphoinositide3-kinase (PI3K) growth and survival pathway (Ward et al., 2014) and reducing sensitivity and tumor cell apoptosis in response to apoptotic stimuli (Breunig et al., 2017). This evidence concerns the gene CDKN1A and neoplasm.